$20 per share is my ultimate target as well. That would value the company at more than a billion dollars. A lot of money to be sure, especially if the drug is only taken to the completion of Phase I by this company. But assuming it performs as advertised, it would certainly be reasonable for big pharma to pay that price for a drug that would produce billions each year in sales.